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aBStract 
CONTEXT AND OBJECTIVE: In children, hepatic steatosis may be related to inborn errors of metabolism 
(IEMs) or to non-alcoholic fatty liver disease (NAFLD). The aim of this study was to assess and characterize 
steatosis of indeterminate cause through morphological and morphometric analysis of liver tissue. 
DESIGN AND SETTING: Cross-sectional study at the Departments of Pathology of Faculdade de Ciências 
Médicas, Universidade Estadual de Campinas (FCM-Unicamp) and Faculdade de Medicina de Botucatu, 
Universidade Estadual Paulista (FMB-Unesp). 
METHODS: Eighteen consecutive liver biopsies obtained from 16 patients of ages ranging from 3 months 
to 12 years and nine months that were inserted in a database in the study period were analyzed using op-
tical microscopy and transmission electron microscopy. Through electron microscopy, the mitochondrial 
density and mean mitochondrial surface area were determined in hepatocytes. Ten patients ranging in 
age from 1 to 14 years were used as a control group. 
RESULTS: “Pure” steatosis was detected, unaccompanied by fibrosis or any other histological alteration. 
Microvesicular steatosis predominated, with a significant increase in mean mitochondrial surface area. 
CONCLUSION: Microvesicular steatosis may be related to primary mitochondrial hepatopathy, especially 
due to reduction of b-oxidation or partial stagnation of oxidative phosphorylation. For these reasons, this 
form of steatosis (which should not be called “pure”) is likely to represent an initial stage in the broad 
spectrum of NAFLD. We have drawn attention to cases of steatosis in the pediatric group, in which the 
microvesicular form predominates, since this may be associated with mitochondrial disorders. 
reSUMO
CONTEXTO E OBJETIVO: Em crianças, a esteatose hepática pode se relacionar a erros inatos do metabo-
lismo (EIMs) ou à doença hepática gordurosa não-alcoólica (DHGNA). O objetivo deste estudo foi avaliar 
e caracterizar esteatose de causa indeterminada por meio de análises morfológica e morfométrica em 
tecido hepático.
TIPO DE ESTUDO E LOCAL: Estudo transversal nos Departamentos de Patologia da Faculdade de Ciências 
Médicas da Universidade Estadual de Campinas (FCM-Unicamp) e Faculdade de Medicina de Botucatu da 
Universidade Estadual Paulista (FMB-Unesp).
MÉTODOS: Foram utilizadas 18 biópsias hepáticas consecutivas obtidas de 16 pacientes com idade va-
riando de 3 meses a 12 anos e 9 meses, inseridas num banco de dados no período do estudo, que foram 
analisadas por microscopia óptica e eletrônica. Na microscopia eletrônica, foi realizada determinação da 
densidade mitocondrial e da área superficial média das mitocôndrias nos hepatócitos. Dez pacientes com 
idade variando de 1 a 14 anos foram usados como grupo controle.
RESULTADOS: Foi detectada esteatose “pura”, não acompanhada por fibrose ou outra alteração histoló-
gica. Foi verificado que, na predominância de esteatose microvesicular, houve aumento significativo da 
área mitocondrial média.
CONCLUSÃO: A esteatose microvesicular pode estar relacionada à hepatopatia mitocondrial primária, 
principalmente devido à redução na b-oxidação ou parcial estagnação da fosforilação oxidativa. Por 
essas razões, esta forma de esteatose (que não pode ser chamada de “pura”) possivelmente represente 
uma fase inicial no amplo espectro da DHGNA. Chamamos a atenção para casos de esteatose no grupo 
pediátrico com predomínio da forma microvesicular, uma vez que pode haver associação com desor-
dens mitocondriais.
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INTRODUCTION
In children, the presence of steatosis is generally related to inborn 
errors of metabolism (IEMs). The clinical presentation varies and 
includes changes to general health condition; neurological, diges-
tive and respiratory disorders; rapid and progressive neurologi-
cal deterioration; myopathy; cardiomyopathy; craniofacial dys-
morphism etc. Some forms of the disease present essentially as 
liver disease with hepatomegaly, jaundice, vomiting, lethargy and 
abnormalities of liver function. 
When these diseases are ruled out after clinical and laboratory 
investigation, non-alcoholic fatty liver disease (NAFLD) should 
be considered. This term, which was initially used for adults, has 
become more inclusive.1 It is currently used to describe all age 
groups, even children.2,3 In more recent years, several studies on 
childhood4 and adolescent hepatic steatosis in cases of NAFLD 
have been conducted, especially in relation to obese children,5-13 
since the prevalence of NAFLD is higher in these types of chil-
dren. In a pediatric group, the risk factors for NAFLD include 
obesity, insulin resistance and hypertriglyceridemia.14 The major 
features are a higher rate in male children, with serum alanine 
aminotransferase (ALT) levels that are usually higher than serum 
aspartate aminotransferase (AST) levels, and with hypertriglyc-
eridemia and vague abdominal pain (which is usually the main 
reason for seeking clinical evaluation).14-16 
According to Mandel et al.17 and Bioulac-Sage et al.,18 child-
hood microvesicular steatosis may be associated with mitochon-
drial abnormalities relating to increased numbers of organelles.18,19 
There is also a correlation with respiratory chain defects and con-
sequently impaired oxidative phosphorylation.20,21 When this 
type of abnormality occurs, transfer of electrons to oxygen mole-
cules generates reactive oxygen species, thus producing superox-
ide anions and hydrogen peroxide.22 Furthermore, with stagna-
tion of mitochondrial oxidative capacity, fatty acids accumulate 
in the cytosol, thus reaffirming the close relationship between 
steatosis and mitochondriopathy. 
The microvesicular form alone may also be associated with 
some clinical conditions, such as Reye’s syndrome, Jamaican 
vomiting sickness and congenital deficiency of b-oxidation.23 In 
an experimental study on pigs, it was observed that the regenera-
tive capacity of the hepatocytes in macrovesicular steatosis was 
more effective than in microvesicular steatosis, thereby implying 
that the latter has a less favorable prognosis.24 
The cases that were studied did not have any clinical associa-
tion with any previously cited factor and the findings were cor-
related with clinical and laboratory data. There is a continuing 
debate on the advisability of performing liver biopsy, because of 
the risk of complications, high costs and lack of effective therapy. 
However, liver biopsy is the only precise diagnostic method, and 
it is essential for grading and staging the disease. Furthermore, it 
enables patient inclusion in clinical screening programs.25,26
OBJECTIVE
The aim of our study was to evaluate and characterize “pure” ste-
atosis in a pediatric group by means of morphological (optical 
and electron microscopy) and morphometric analysis.
MATERIAL AND METHODS
All pediatric patients who were diagnosed as presenting morpho-
logical steatosis by means of optical microscopy and examination 
of liver fragments processed for transmission electron micros-
copy in the Department of Pathology of the School of Medical 
Sciences of Universidade Estadual de Campinas (FCM-Unicamp) 
and the Department of Pathology of Faculdade de Medicina de 
Botucatu (FMB) between 1993 and 2007 were retrospectively 
selected by means of a database search (specific records from 
liver biopsies). Cases in which the cause of steatosis was estab-
lished (IEM, obesity, diabetes, inherited metabolic disorders, 
malnutrition, viral hepatitis, Wilson’s disease, drug use and/or 
total parenteral nutrition) were subsequently excluded. Sixteen 
patients whose cause of steatosis could not be identified were 
selected. These patients’ ages ranged from three months to 12 
years and nine months. Their heights ranged from 47 to 154.5 
cm and their weights ranged from 3.15 to 51.50 kg. A review of 
all previously selected liver biopsies was undertaken: 18 samples 
were analyzed, because one patient underwent three biopsies 
(samples 12, 13 and 14). 
The control group was composed of liver biopsies obtained 
from ten patients aged from one to 14 years who presented nor-
mal physical development. In this group, the indications for liver 
biopsy were similar to those in the study group, i.e. vague abdom-
inal pain and/or minimal hepatomegaly associated with slightly 
and persistently elevated hepatic enzyme levels. The diagnoses for 
the control individuals were normal, confirmed either from opti-
cal or from electron microscopy findings. In all of these patients, 
the blood glucose levels were always normal. All the clinical data 
were obtained by consulting patient medical records. The present 
study was approved by the Research Ethics Committee of FCM-
Unicamp (process no. 523/2004).
The liver specimens were obtained by means of percutaneous 
biopsy and were processed using optical microscopy and trans-
mission electron microscopy (TEM). For optical microscopy, the 
specimens were fixed in 10% formalin and processed for embed-
ding in Paraplast Plus. The 5 mm sections were stained with 
hematoxylin-eosin to semi-quantitatively analyze two param-
eters: a) intensity of total steatosis (macro and microvesicular); 
and b) estimated percentage of hepatocytes affected by microve-
sicular steatosis, compared with hepatocytes affected by mac-
rovesicular steatosis. The intensity of total steatosis was classified 
from (1) to (4), as follows: (1) 5% to 25% of tissue affected by 
steatosis; (2) 25 to 50% of tissue affected; (3) 50 to 75% of tissue 
affected; and (4) more than 75% of tissue affected. To determine 
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Table 1. Description of some parameters evaluated from the 16 patients studied (18 samples) 
Group Sample Age Sex
BMI
(kg/m2)
AST
(U/I)
ALT
(U/I)
GGT
(U/I)
Chol
(mg/dl)
Trig
(mg/dl)
Total 
steatosis
Microvesicular 
steatosis
Reference 
values
AST < 37 
U/I
ALT < 40 U/I GGT < 40 U/I
total 
cholesterol  
< 200 mg/dl
triglycerides 
< 120 mg/dl
Macrovesicular
01 1y 11m F 18.7 20 72 ni 134 46 4 40%
03 11y M 21.6 68 99 28 219 109 3 45%
08 1y 2m M 15.7 73 48 39 216 172 4 20%
11 5m M 14.6 87 386 554 131 347 4 25%
12 4y 6m M 17.5 47 48 20 ni 34 2 40%
14 1y 1m M 15.9 25 25 37 146 51 4 50%
18 6m F 13.5 119 204 585 133 476 4 5%
Microvesicular
02 10m F 15.7 75 71 ni 216 1330 4 55%
04 6y F 14.3 304 104 340 103 516 3 70%
05 3y 8m F 14.9 24 17 15 172 54 1 70%
06 1y 1m M 17.0 75 50 384 144 152 3 70%
07 5m F 12.8 242 151 ni ni ni 3 75%
09 3m M ni 14 19 212 182 421 3 70%
10 4m F 13.7 37 63 197 172 455 3 75%
13 2y M 16.5 26 22 50 156 54 4 60%
15 10 m M 15.8 47 53 31 105 87 4 80%
16 11y 1m M 14.7 20 18 ni 166 75 2 95%
17 12y 9m M ni 39 63 257 281 286 3 75%
BMI = body mass index; ni = nothing included; y = years; m = months; F = female; M = male; AST = aspartate aminotransferase; ALT = alanine aminotransferase; 
GGT = gamma-glutamyl transpeptidase; Chol = total cholesterol; Trig = triglycerides. 
the percentage of hepatocytes affected by microvesicular steato-
sis, all cells present in the fragments analyzed were counted (cells 
with small-droplet steatosis and those with large-droplet steato-
sis) and then the percentages of each cell type were calculated. 
Specimens processed for TEM were fixed in a 2.5% glutaralde-
hyde solution, postfixed in a 1% osmium tetroxide solution and 
embedded in araldite resin. Ultrathin sections (70-80 nm) were 
observed under a LEO 906 (Zeiss) electron microscope. For each 
patient, a liver tissue block was analyzed to determine the mito-
chondrial surface area in 10 microscope fields at a magnification 
of 6,000 x and the mean mitochondrial density, by counting the 
number of mitochondria present in 10 hepatocytes. Since this 
was a retrospective study, identification of the liver acinus zone 
at the time of inclusion was not a cause for concern. The acinus 
zone could not be characterized in this study because of the small 
dimensions of the TEM blocks. However, hepatocytes were ran-
domly selected in all cases, thereby minimizing the error relating 
to sampling.
The results obtained were compared with the mean values 
found in the control group of patients. The inclusion criteria for 
the control group were that these individuals should be under 
14 years of age and present a liver biopsy that was diagnosed 
as normal (n = 10). In both analyses, image capture was ana-
lyzed with the aid of the TPS Dig 1.30 software. The difference in 
steatosis between the patients and controls was evaluated using 
analysis of variance (ANOVA) with log transformation. P val-
ues < 0.05 were arbitrarily taken to be significant (“acceptable 
error limit”).
RESULTS
All the samples were described as having fatty liver, without 
fibrosis and/or deposition in hepatocytes or Kupffer cells. For 
each sample evaluated, Table 1 shows the total steatosis values 
obtained by means of semiquantitative analysis and the microve-
sicular steatosis values obtained by means of estimated analysis. 
The total steatosis ranged from one to four and the microvesicu-
lar steatosis ranged from five to 95%. Considerable variation was 
found in the degree of steatosis, as well as in the percentage of 
microvesicular steatosis compared with macrovesicular steato-
sis. Because of this variation, the patients were allocated into two 
groups: the first group was composed of patients with predomi-
nantly (> 50%) microvesicular steatosis (n = 11); and the second 
group was composed of patients with predominantly (≤ 50%) 
macrovesicular steatosis (n = 7).
Marked variation in hepatic enzyme values was observed. 
The AST levels ranged from 20 to 304 U/I; ALT from 17 to 386 
U/I; and gamma-glutamyl transpeptidase (GGT) from 15 to 
585 U/I. In Table 1, the biochemical parameters, weight and 
height of each patient are shown.
Analysis on the mitochondrial ultrastructure showed that the 
most frequent morphological abnormalities were megamitochon-
dria, with or without crystalline inclusions, and a highly irregular 
mitochondrial shape, with degenerative changes (decreased elec-
tron density and loss of cristae).
Morphometric analysis on mitochondrial density showed 
that there were no significant differences between the con-
trol group, microvesicular steatosis group and macrovesicular 
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Figure 1. Mean mitochondrial density in the hepatocytes from patients 
with steatosis, compared with patients in the control group. Analysis of 
variance (ANOVA) with log transformation. 
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Figure 2. Electron micrographs showing differences in relation to mitochondrial density. A: Hepatocyte from a subject in the control 
group; B: Hepatocyte from a patient with macrovesicular steatosis; C: Hepatocyte from a patient with microvesicular steatosis.
steatosis group, as demonstrated in Figure 1. Images showing the 
differences in the quantities of mitochondria in the hepatocytes 
are presented in Figure 2. 
Analysis on the mean mitochondrial surface area showed 
that there was a significant difference between the microvesicu-
lar steatosis group and the control and macrovesicular steatosis 
groups. These results are presented in Figure 3 and images are 
shown in Figure 4. 
DISCUSSION
Since mitochondria are the sites for many metabolic processes 
(such as tricarboxylic acid production, fatty acid β-oxidation, 
synthesis of urea and other substances, and use of glucose and 
fatty acids as fuels for ATP synthesis), a disorder in any of these 
mechanisms may cause severe damage to the cell and thus to the 
tissue. Respiratory chain defects are not rare and are known to 
cause early liver failure in infancy,21 thereby leading to a change 
in fatty acid oxidation.27 Changes to mitochondrial β-oxidation 
may result in accumulation of fatty acids in the cytosol, and this 
is typically represented by microvesicular steatosis.28,29
In our study, a significant elevation in mean mitochondrial 
surface area was observed, and this proved to be substantial in 
the patients with predominantly microvesicular steatosis. In con-
trast, the mitochondria in the patients with predominantly mac-
rovesicular steatosis were considered to be normal in size. These 
results corroborate the reports by Sherlock and Dooley30 indicat-
ing that microvesicular steatosis is of greater clinical importance 
and may progress in a more troubling manner.
Many other reports on the relationship between steatosis and 
mitochondrial alterations have been published in the literature. 
Studies by Sokol and Treem27 have reported that steatosis in neo-
natal liver failure is related to increased mitochondrial density, 
with an occasional increase in mitochondrial size. Mandel et al.17 
observed mitochondrial abnormalities in the matrix and cris-
tae, and also an increase in the total number of mitochondria, 
in cases of microvesicular steatosis. Bioulac-Sage et al.18 reported 
mitochondrial proliferation (“oncocytic” changes) in patients 
with microvesicular steatosis.
Despite an evident increase in mitochondrial size in patients 
with microvesicular steatosis, changes to mitochondrial den-
sity were not clearly expressed in this morphometric model. To 
explain this result, our suggestion is that the normal distribu-
tion of mitochondria in the cytosol becomes altered because of 
the existence of lipid vacuoles in hepatocytes. Changes to mito-
chondrial distribution then disrupt the regularity of the outcome, 
especially when comparing the results from patients with steato-
sis to those from the control group (in which there are no lipid 
vacuoles in the cell).
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Figure 4. Electron micrographs showing differences in relation to mean mitochondrial surface area in the hepatocytes. A: Mitochondria 
in the hepatocytes from a subject in the control group; B: Mitochondria in the hepatocytes from a patient with macrovesicular steatosis; 
C: Mitochondria in the hepatocytes from a patient with microvesicular steatosis showing considerable dimensions (megamitochondria) 
and crystalline inclusions.
Figure 3. Mean mitochondrial surface area in the hepatocytes 
from patients with steatosis compared with patients in the control 
group.  (*) represents a significant difference between the group 
with microvesicular steatosis, the control group and the group with 
macrovesicular steatosis. Analysis of variance (ANOVA) with log 
transformation (P < 0.05).
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In our case study, 64% of the patients with microvesicular 
steatosis and 57% of the patients with macrovesicular steatosis 
showed an elevation in at least one hepatic serum aminotrans-
ferase. Some authors such as Rashid and Roberts15 and Molleston 
et al.16 have reported higher rises in AST than in ALT. However, 
this relationship is quite typical of alcoholic hepatitis, in which 
the AST/ALT ratio is greater than one.2 In our case study, only 
39% of the patients with steatosis (of both types) presented ele-
vated serum transaminase levels with an AST/ALT ratio greater 
than one. Elevated serum aminotransferase levels seem to show 
no direct relationship with either type of steatosis. Thus, no rela-
tionship with increased mitochondrial volume is found, since the 
enzyme levels vary widely, both in patients with predominantly 
microvesicular steatosis and in those with predominantly mac-
rovesicular steatosis. 
Another indication of compromised mitochondria is the fre-
quent observation of megamitochondria, often showing crys-
talline inclusions. Such findings have been correlated with Wil-
son’s disease31 and nonalcoholic steatohepatitis (NASH).32 More 
recently, it has been indirectly correlated with oxidative stress in 
NAFLD cases.33,34 
The mechanisms that induce mitochondrial “hypertrophy” 
remain obscure. However, changes to the respiratory chain or 
to other mitochondrial metabolic enzymes, whether inborn or 
acquired, may lead to an increase in b-oxidation and partial stag-
nation of oxidative phosphorylation (OxP). We hypothesize that 
an increase in mitochondrial volume occurs as a consequence. 
As a result, the volumes of the inner membrane (and cristae) and 
inner membrane space (sites relating to b-oxidation and OxP) 
increase in an attempt to compensate for metabolic processes that 
were partially or totally interrupted. Taking into account the “two-
hit” hypothesis proposed by Day and James35 to explain the patho-
genesis of NAFLD, it is important to note that steatosis by itself 
does not cause the development of liver disease. However, it is a 
factor that can sensitize the liver to the damaging effects of a “sec-
ond hit.” Therefore, factors causing innocuous stress in healthy 
livers may lead to the development of NASH in steatotic livers.36
The results from this study have contributed substan-
tially towards evaluations on childhood steatosis of indetermi-
nate cause, drawing close attention to cases with predominantly 
Original article | Silva GH, Hessel G, Coelho KIR, Escanhoela CAF
222     Sao Paulo Med J. 2011; 129(4):217-23
microvesicular steatosis. No similar studies on pediatric groups 
have been published in the literature, and we would particularly 
like to highlight that the data on the control group in this study, 
which has also never previously been published, may be useful as 
a reference for conducting other electron microscopy studies on 
pediatric livers. 
CONCLUSION
It may be concluded from our results that changes to serum 
transaminases and the presence of macrovesicular steatosis in 
this pediatric group did not correlate with changes to mitochon-
drial density or size. In addition, increased mitochondrial size 
was probably a morphological expression relating to deranged 
beta-oxidation and partial stagnation of oxidative phosphoryla-
tion. This therefore supports the hypothesis that there may be 
a mild form of primary mitochondrial hepatopathy, which may 
then progress in a more worrisome manner, especially as a sec-
ond hit.
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